Adial Pharmaceuticals

NASDAQ: ADIL ↗$6.21 USDMicro-cap (~$4.99/share, Aug 2026) MCAP

#Alcohol use disorder #Ulcerative colitis #Pain (non-opioid)

Adial Pharmaceuticals (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, focused on therapeutics for addiction and related disorders. Its lead program, AD04, is a genetically targeted serotonin-3 receptor antagonist being advanced through a new Phase 3 clinical trial program for alcohol use disorder in patients with certain target genotypes. Following the June 2026 acquisition of Azora Therapeutics, the pipeline also includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist in development for ulcerative colitis, plus earlier-stage candidates for non-opioid pain reduction. On August 17, 2026, shares rose 25.38% after the company reported Q2 2026 results and a business update highlighting the Azora acquisition and the AD04 Phase 3 path.

Company Info

Sector:Clinical-stage biopharmaceuticals — addiction medicine and inflammation

Headquarters:Glen Allen, Virginia, USA

Founded:2010

Website:www.adial.com/

Clinical Development Pipeline

AD04

Target: Serotonin-3 (5-HT3) receptor antagonist

Alcohol use disorder (genetically targeted patient subgroups)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

AT177

Target: Colon-targeted aryl hydrocarbon receptor (AhR) agonist

Ulcerative colitis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Cary John Claiborne

Chief Executive Officer, President and Director

Vinay Shah

Chief Financial Officer and Treasurer

Matthew Davidson

Chief Development Officer and Director

Careers & Job Openings

See all open roles

Apply Now →